Page 2 - Csl Behring News Today

US regulators approved CSL Behring's hemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs $3.5 million a dose, making it the most expensive medicine in the world.

CSL Behring's hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, the one-time treatment will save money over time.

Following success of Hizentra App, CSL Behring and BrightInsight expand partnership to build apps for rare disease medicines across the globe...

MELBOURNE, Australia and KING OF PRUSSIA, Pennsylvania Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL’s three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the decades ahead.

On Twitter and over email, Fetterman’s campaign manager Brendan McPhillips laid into what he called a “scam PAC” that was “using John’s name and likeness for their own fundraising.”

MARBURG, GERMANY The new facility, once fully open later this calendar year, will be CSL’s largest R&D site under one roof, with more than 500 team members working in a state-of-the-art facility offering access to promising scientific partners and talent.

BrightInsight developed the Disease Management Solution to help biopharma and medtech companies bring their Software as a Medical Device (SaMD)  to market faster, according to BrightInsight CEO and Co-founder Dr. Kal Patel.

/PRNewswire/ -- Global biotherapeutics leader CSL Behring and renowned portrait photographer Rankin have teamed up to launch Portraits of Progress, a...

The 500 million international units (IUs) will include product specifically manufactured for donation allowing for a longer shelf life and enabling more people around the world to access life-saving therapy.

/PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating...